Skip to content

EFFICASY OF SIDDHA FORMULATION ââ?¬Å?KANDANGAARI NEIââ?¬? IN THE MANAGEMENT OF ââ?¬Å?SWASAKAASAMââ?¬?(BRONCHIAL ASTHMA).

A CLINICAL EVALUATION OF SIDDHA FORMULATION ââ?¬Å?KANDANGAARI NEIââ?¬? IN THE MANAGEMENT OF ââ?¬Å?SWASAKAASAMââ?¬?(BRONCHIAL ASTHMA).

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/035304
Enrollment
30
Registered
2021-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

None listed

Sponsors

NATIONAL INSTITUTE OF SIDDHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18-60 years. Sex: Male, Female & Transgender. Patients with a clinical symptoms of Sneezing, Rhinitis, Dyspnoea, Cough with or without expectoration, Wheeze, Tightness of chest. Wheezing more than 3 weeks. Night time wheezing more than one day/week. Asthma sometimes interferes with normal daily activities. Status asthmaticus Patients who are willing to take radiological investigation and provide blood for lab investigation. Patients who are willing to estimate volume of air forcibly expired after a deep inspiration by using PFT.

Exclusion criteria

Exclusion criteria: Tuberculosis Restrictive lung disease COPD Emphysema Pleural effusion Cardiac disease Renal disease Diabetic mellitus Symptoms of acute severe illness like Chest pain, nausea, vomiting, high fever, dyspnea Recent haemoptysis Pneumothorax Recent history of abdominal, thoracic, or cerebral aneurysm Anaemia Sleep apnoea

Design outcomes

Primary

MeasureTime frame
Primary outcome is assessed by comparing the lung volumes and capacities in pre and post treatment pulmonary function test.Timepoint: Total 12 Months 1) 1st - 3rd month - Screening and Enrollment of study population (patients). 2) 4th - 9th month - Conduct of the study 3) 10th month - Data collection 4) 11th month - Data analysis 5) 12th month - Outcome arrive and Journal publication.

Secondary

MeasureTime frame
Secondary outcome is assessed by comparing clinical signs and symptoms, laboratory parameters of IgE, AEC before and after treatmentTimepoint: Total 12 Months 1) 1st - 3rd month - Screening and Enrollment of study population (patients). 2) 4th - 9th month - Conduct of the study 3) 10th month - Data collection 4) 11th month - Data analysis 5) 12th month - Outcome arrive and Journal publication.

Countries

India

Contacts

Public ContactDRHNALINISOFIA

NATIONAL INSTITUTE OF SIDDHA

dr.h.nalinisofia@gmail.com8939899363

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026